GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. - Wikidata - wikimedia - TriplyDB

GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

http://www.wikidata.org/entity/Q34163028

about

Biologic complexity in sickle cell disease: implications for developing targeted therapeutics Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration Genomic approaches to identifying targets for treating β hemoglobinopathies Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration Anemia: progress in molecular mechanisms and therapies Glycotherapy: new advances inspire a reemergence of glycans in medicine Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Biomarkers and recent advances in the management and therapy of sickle cell disease Advances in sickle cell therapies in the hydroxyurea era Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia An Analysis of Trafficking Receptors Shows that CD44 and P-Selectin Glycoprotein Ligand-1 Collectively Control the Migration of Activated Human T-Cells.Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability.Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation Synthesis of multivalent carbohydrate mimetics with aminopolyol end groups and their evaluation as L-selectin inhibitors.Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease.Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells G-CSF induces membrane expression of a myeloperoxidase glycovariant that operates as an E-selectin ligand on human myeloid cells Glycomics hits the big time Glycans and glycan-binding proteins in immune regulation: A concise introduction to glycobiology for the allergist Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells.The emerging importance of α-L-fucose in human breast cancer: a review.Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis.Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo.Platelet-neutrophil interactions under thromboinflammatory conditions Targeting iNKT cells for the treatment of sickle cell disease.Selectins: initiators of leucocyte adhesion and signalling at the vascular wall Life in the fast lane: mammalian disease models in the genomics era.Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.Glycobiology simplified: diverse roles of glycan recognition in inflammation Endothelin-1 receptor antagonists regulate cell surface-associated protein disulfide isomerase in sickle cell disease.Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.

P2860

Q21284789-99F2175F-4CA5-40CD-B826-09EB12B12B66 Q26742061-6E448069-58B4-4740-96FD-8AE6D262847E Q26799214-B47DB48A-82F5-42EC-9D7F-7CE78FD7EA4A Q26995291-0D7DB46D-D453-4A47-9D4E-B39D873A2B87 Q27023172-BDC60162-619B-4143-9986-F5AF9D426EF8 Q27027997-56A7F4A2-8CB8-4A32-84ED-0F84C4D569A8 Q27303155-F34FA37C-C757-4D8E-81E3-8A9E9552B647 Q28082462-7730D835-ACB5-4635-887A-C63F85E0C955 Q28088552-A883A134-AAE6-44F4-8C12-E5248FB52AFD Q28540243-9FCAFB93-77FF-493B-95F2-42E8DE0732CA Q29994863-EE91020C-C4A9-482D-81EF-FCAD93ABAE15 Q30498050-05CA1815-5979-4353-A28A-F3B4F51A5C1C Q30506249-ECB86BCA-A83A-491D-813A-4AE0394C6DA3 Q30525565-26896930-177B-43E5-B60A-60304E8F1EFD Q30574476-160C9F4E-8D35-45B8-964B-8687C777EBEC Q30575274-DAB3BB89-554B-4B2D-A705-5872F40A8408 Q30977626-B6204C60-815C-43E5-9520-8D032740A939 Q33688938-948CA350-FF2A-4A75-AFBD-6034E9E6AB27 Q33749670-65B3534A-982D-4827-A31F-FEFB525A995B Q33778831-AB448190-CB2B-4652-832B-C25D9B9E9BE2 Q33971650-FAADEEA9-BE51-447B-9513-A1D8164D751C Q34432774-E4E18176-823E-4E86-8700-73F09B6C0467 Q35163983-69BF09BA-4A95-40E9-BA67-06961E38C435 Q35164415-49784033-E3CA-4BEE-923F-1134BC7EADDC Q35165332-12954237-752A-4F8C-8230-83D8065159C3 Q35172546-56135518-B8F2-4F75-BCEE-3C87E4A9DED1 Q35533604-6A3480EF-5283-484C-BB42-033F6E38C79E Q35537053-FDFE2792-1C7C-4728-BC19-DA001583DD1C Q35580452-EAD29A7A-CFBC-4B73-964A-7FFD301BD4CE Q35779411-CB059470-A579-49B0-8945-B5F35CB0E1F8 Q35893688-E7EC7F31-A38C-48FD-AE85-6C28D8F1F1DA Q36117363-E40673CB-A7D6-4CB0-94E9-6A9661A2EF2B Q36135110-F28A941A-1F0B-4F77-9044-9679EA514299 Q36322782-4DE68A73-17EF-416B-B59B-95BB834ECF7B Q36596850-0235EF93-20DB-41C6-9205-44D975ECEA17 Q36596855-AA32FFCB-9D92-4EEA-B469-E9FD9A16D06B Q37111287-8B5F6743-B59F-4E0A-8FB7-6147A3B287F8 Q37245989-D68AD66B-2D12-46FC-ACCE-2F7DEE9279FD Q37370659-CEB7F349-B0C1-4343-96CB-D7ACF0322444 Q37618816-24738D85-DE03-47FE-B85D-3BF4813999EE

P2860

GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

http://www.wikidata.org/entity/Q34163028

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@ast

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@en

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@nl

type

label

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@ast

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@en

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@nl

prefLabel

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@ast

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@en

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@nl

P1433

Q34163028-C41297B7-DFB4-4B9E-95A7-2AFD09DAB17D

P1476

Q34163028-E83AFE4C-473D-4D2B-BCEB-2A387773ECA0

P2093

Q34163028-0A19E509-8AF6-413A-84A6-4AC248728582

Q34163028-399F079D-9782-41D1-B384-5185D68CC4F9

Q34163028-5AF51738-96B7-4121-8A93-8A2465E8D6D8

Q34163028-6ABB4CCF-14EA-494B-ABD3-933F90BDB9D0

Q34163028-C43AABBC-C781-41C4-8150-BC826096F356

Q34163028-E616DD49-313F-4E80-9AB8-F85E0909B281

P2860

Q34163028-0D863697-C38D-4AFD-AD6C-70A4952122BB

Q34163028-128EE024-94D9-490A-AB5D-243BC8B35F4C

Q34163028-199FF2BB-1E57-4DED-9B7B-FFB196353A06

Q34163028-22657ADB-52E2-430F-8DA8-C160E6B787F1

Q34163028-26DD1AB9-0204-4F3D-9F7C-D5E3CF9645F9

Q34163028-379F3F82-E92F-490E-B0F0-399666934384

Q34163028-38689416-2449-4616-93BA-6509CE39F9A0

Q34163028-3D98B960-45EB-4FB8-9711-44E35EE6DDD0

Q34163028-4ADD0985-2D16-42A4-A302-52CD7608368C

Q34163028-63E0782C-E33A-4B62-A19E-7EA2848788EB

P304

Q34163028-E12F45F3-8536-4457-9BB1-9261B0BD6EC5

P31

Q34163028-9DD94C1B-19ED-40CF-B181-158D3E54DA30

P356

Q34163028-14A2DB99-F085-4555-B69C-657CCB5E4444

P407

Q34163028-9DF2DC27-FE00-48E1-8F01-375640DE2D65

P433

Q34163028-9731B8A9-0AC6-4D2B-A2BC-19200056D866

P478

Q34163028-A651E40B-C3F0-4278-B9A1-32617269BE66

P577

Q34163028-33E83C41-97D5-44C5-96BE-F03C6B0B151C

P5875

Q34163028-DC708F25-8A0C-409C-B29B-D1DC833DC9A8

P698

Q34163028-08EF9061-9A86-4CC3-9D77-25E8F39FB628

P921

Q34163028-72D9D00A-064E-46CF-8A70-D7F0CC6ABD35

P932

Q34163028-98074692-55BA-4FB9-A805-C12B4EA3A4D5

P356

BLOOD-2009-12-260513

P1433

P1476

GMI-1070, a novel pan-selectin ...... cclusions in sickle cell mice.

@en

P2093

Arun Sarkar

http://www.w3.org/2001/XMLSchema#string

Beat Ernst

http://www.w3.org/2001/XMLSchema#string

John L Magnani

http://www.w3.org/2001/XMLSchema#string

John T Patton

http://www.w3.org/2001/XMLSchema#string

Jungshan Chang

http://www.w3.org/2001/XMLSchema#string

Paul S Frenette

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting selectins and selectin ligands in inflammation and cancer

The role of selectins in inflammation and disease

Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis

Sickle-cell disease

Distinct phenotype of E-selectin-deficient mice. E-selectin is required for slow leukocyte rolling in vivo.

Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm

Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury

Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation.

Epitope mapping of sialyl Lewis(x) bound to E-selectin using saturation transfer difference NMR experiments.

Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin.

P304

1779-1786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-12-260513

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44635766

http://www.w3.org/2001/XMLSchema#string

P698

20508165

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

2947397

http://www.w3.org/2001/XMLSchema#string